NasdaqCM - Nasdaq Real Time Price USD

NeuroSense Therapeutics Ltd. (NRSNW)

0.2499
-0.0501
(-16.70%)
At close: May 14 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for NRSNW

Recent News: NRSNW

View More
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
Benzinga 2 days ago
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
PR Newswire 7 days ago
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
PR Newswire 20 days ago
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
PR Newswire last month
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
PR Newswire last month
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
PR Newswire last month

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
Business Wire last month

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
Business Wire last month
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
PR Newswire 4 months ago
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
PR Newswire 4 months ago
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
PR Newswire 4 months ago
View More

Related Tickers

ABRT.CN Albert Labs International Corp.
0.0050
0.00%
 
BTTX Better Therapeutics, Inc.
0.0002
0.00%
 
1CVAC.MI CureVac N.V.
3.0800
+0.79%
 
F6T.DU Fate Therapeutics Inc
0.8106
-5.28%
 
ESLAW Estrella Immunopharma, Inc.
0.0807
-4.16%
 
P0F.F Egetis Therapeutics AB (publ)
0.2975
-2.94%
 
1TB0.SG Orphazyme AS
137.50
+0.36%
 
328.SG MeiraGTx Holdings PLC
4.0600
-0.49%
 
BSFAF BSF Enterprise Plc
0.0350
+75.00%
 
688068.SS Beijing Hotgen Biotech Co., Ltd.
98.98
-2.65%